Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Surg Endosc ; 37(12): 9062-9069, 2023 12.
Article in English | MEDLINE | ID: mdl-37964092

ABSTRACT

OBJECTIVE: Sphincter of Oddi dysfunction (SOD) has been used to describe patients with RUQ abdominal pain without an etiology. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of ES (endoscopic sphincterotomy) for SOD. METHODS: The study methodology follows the PRISMA guidelines. A comprehensive search was conducted using MEDLINE and EMBASE databases for RCTs with ES in patients with SOD. The primary outcome assessed was the improvement of abdominal pain after ES/sham. A random effects model was used to calculate pooled estimates for each outcome of interest. RESULTS: Of the initial 55 studies, 23 were screened and thoroughly reviewed. The final analysis included 3 studies. 340 patients (89.7% women) with SOD were included. All patients had a cholecystectomy. Most included patients had SOD type II and III. The pooled rate of technical success of ERCP was 100%. The average clinical success rate was 50%. The pooled cumulative rate of overall AEs related to all ERCP procedures was 14.6%. In the sensitivity analysis, only one study significantly affected the outcome or the heterogeneity. CONCLUSION: ES appears no better than placebo in patients with SOD type III. Sphincterotomy could be considered in patients with SOD type II and elevated SO basal pressure.


Subject(s)
Sphincter of Oddi Dysfunction , Sphincter of Oddi , Humans , Female , Male , Sphincterotomy, Endoscopic/adverse effects , Sphincterotomy, Endoscopic/methods , Sphincter of Oddi Dysfunction/surgery , Sphincter of Oddi Dysfunction/etiology , Sphincter of Oddi/surgery , Cholangiopancreatography, Endoscopic Retrograde/methods , Manometry , Abdominal Pain/etiology
2.
Dig Dis Sci ; 63(6): 1506-1512, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29594977

ABSTRACT

BACKGROUND: Eosinophilic esophagitis (EoE) is the most common cause of dysphagia and esophageal food impaction (EFI) in the USA, Western Europe, and Australia. In Mexico, the uncomplicated form of this disease is infrequent, and prevalence in patients with EFI is unknown. AIMS: To determine the prevalence and causes of EFI, endoscopic and therapeutic aspects, and establish the prevalence of biopsy-proven EoE in patients with EFI. METHODS: Diagnostic upper gastrointestinal endoscopy reports from January 2011 to December 2016 were retrospectively reviewed. Patients with therapeutic procedures, gastrointestinal hemorrhage, or non-food foreign body impaction were excluded. The number of patients with EFI was determined. Additionally, patients with esophageal biopsy were retained for EoE prevalence calculation. The diagnosis of EoE was defined with the presence of eosinophil infiltration count ≥ 15/high-power field with or without typical endoscopic abnormalities. RESULTS: A total of 4700 reports of the same number of patients were selected; 2209 were males (47%) with a mean age of 57.6 ± 12.3 years (range 14-93). We identified 36 patients with EFI (0.76, 95% CI 0.51-1.01), 16 males (44.4%) with a mean age of 54.9 ± 19.7 (range 22-92). Esophageal biopsies were obtained in 17/36 (47.2%) cases. The diagnosis of EoE was confirmed in 2 patients (11.7%). Peptic stenosis was the most frequent cause of EFI. CONCLUSIONS: EoE is an infrequent cause of EFI in the Mexican population (11.7%). EoE had the lowest prevalence compared to that reported in Caucasian populations. The prevalence of EFI was also low.


Subject(s)
Deglutition Disorders/epidemiology , Deglutition , Eosinophilic Esophagitis/epidemiology , Esophagus/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Deglutition Disorders/pathology , Deglutition Disorders/physiopathology , Deglutition Disorders/therapy , Eosinophilic Esophagitis/pathology , Eosinophilic Esophagitis/physiopathology , Eosinophilic Esophagitis/therapy , Esophagoscopy , Esophagus/physiopathology , Female , Humans , Male , Mexico/epidemiology , Middle Aged , Predictive Value of Tests , Prevalence , Prognosis , Retrospective Studies , Risk Factors , Young Adult
4.
Ann Hepatol ; 15(6): 902-906, 2016.
Article in English | MEDLINE | ID: mdl-27740524

ABSTRACT

 Background & Aims. It is unclear whether portal vein thrombosis (PVT) unrelated to malignancy is associated with reduced survival or it is an epiphenomenon of advanced cirrhosis. The objective of this study was to assess clinical outcome in cirrhotic patients with PVT not associated with malignancy and determine its prevalence. MATERIAL AND METHODS: Retrospective search in one center from June 2011 to December 2014. RESULTS: 169 patients, 55 women and 114 men, median age 54 (19-90) years. Thirteen had PVT (7.6%). None of the patients received anticoagulant treatment. The PVT group was younger (49 [25-62] vs. 55 [19-90] years p = 0.025). Child A patients were more frequent in PVT and Child C in Non-PVT. Median Model for End Stage Liver Disease (MELD) score was lower in PVT (12 [8-21] vs. 19 [7-51] p ≤ 0.001) p ≤ 0.001). There was no difference between upper gastrointestinal bleeding and spontaneous bacterial peritonitis in the groups. Encephalopathy grade 3-4 (4 [30.8%] vs. 73 [46.8%] p = 0,007) and large volume ascites (5 [38.5%] vs. 89 [57.1%] p= 0,012) was more common in non-PVT. Survival was better for PVT (16.5 ± 27.9 vs. 4.13 ± 12.2 months p = 0.005). CONCLUSIONS: We found that PVT itself does not lead to a worse prognosis. The most reliable predictor for clinical outcome remains the MELD score. The presence of PVT could be just an epiphenomenon and not a marker of advanced cirrhosis.


Subject(s)
Liver Cirrhosis/epidemiology , Portal Vein , Venous Thrombosis/epidemiology , Adult , Aged , Aged, 80 and over , Computed Tomography Angiography , Disease Progression , Female , Humans , Kaplan-Meier Estimate , Liver Cirrhosis/diagnosis , Liver Cirrhosis/mortality , Male , Mexico/epidemiology , Middle Aged , Phlebography/methods , Portal Vein/diagnostic imaging , Predictive Value of Tests , Prevalence , Prognosis , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors , Ultrasonography, Doppler , Venous Thrombosis/diagnostic imaging , Venous Thrombosis/mortality , Young Adult
5.
J Dig Dis ; 17(2): 128-31, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26630456

ABSTRACT

There are many autoimmune diseases associated with primary biliary cholangitis (PBC), known as primary biliary cirrhosis; however, the association between PBC and warm autoimmune hemolytic anemia (wAIHA) has rarely been reported. It is documented that hemolysis is present in over 50% of the patients with chronic liver disease, regardless of the etiologies. Due to the clear and frequent relationship between PBC and many autoimmune diseases, it is reasonable to suppose that wAIHA may be another autoimmune disorder seen in association with PBC. Here we reported a 53-year-old female patient diagnosed with wAIHA associated with PBC.


Subject(s)
Anemia, Hemolytic, Autoimmune/complications , Liver Cirrhosis, Biliary/complications , Anemia, Hemolytic, Autoimmune/drug therapy , Biopsy , Drug Therapy, Combination , Female , Glucocorticoids/therapeutic use , Humans , Liver/pathology , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/drug therapy , Liver Cirrhosis, Biliary/pathology , Middle Aged , Prednisolone/therapeutic use , Ursodeoxycholic Acid/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL